Login
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp.

pasithea.com

What Do They Do?

Develops experimental medicines for patients with inherited disorders, cancers driven by cell-signaling changes, and other diseases, including brain disorders.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −117% (Loss)
vs −$3M in Q3 FY2025
  • Aug 20, 2026 Nasdaq extended the deadline to regain minimum bid-price compliance The company has until February 16, 2027, to meet Nasdaq’s $1.00 minimum bid price requirement; failure could lead to delisting.

Stated focus The older report focused on central nervous system disorders and RASopathies; the latest describes a focus on RASopathies and MAPK pathway-driven tumors, among other diseases.

ALS program The older report described an ALS drug program; the latest says the company stopped its further development.

Who Do They Compete With?

Competes with GSK, Novartis, Pfizer, Genentech, Verastem, AstraZeneca, Merck &, SpringWorks Therapeutics, Array BioPharma, Chia Tai Tianqing Pharmaceutical Group, Healx, Infixion Bioscience, Shanghai Fosun Pharmaceutical (Group), Shanghai Kechow Pharma, and NFlection Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support